The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Bone health expert Debi Robinson joined Gayle Guyardo, host of the globally syndicated health and wellness show Bloom, to ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

Dad felt like he was ‘walking in flippers’ before incurable cancer diagnosis - Mart Roe’s symptoms were initially dismissed ...

In 2025, the American Cancer Society estimates that 36,110 new cases of multiple myeloma will be diagnosed, affecting about 20,030 men and 16,080 women. Who gets multiple myeloma?

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while ...

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: C=Hypercalcemia R=Renal insufficiency A=Anemia B ...

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...